Fed. Circ. Backs Pfizer Win In Paxlovid Patent Dispute
The Federal Circuit on Tuesday refused to revive a patent that Pfizer was accused of infringing through its blockbuster Paxlovid COVID-19 treatment, rejecting the patent owner's arguments over what it said...To view the full article, register now.
Already a subscriber? Click here to view full article